ストックスクリーナーアプリを入手
16.84
0.18%
-0.03
アフターアワーズ：
16.86
0.02
+0.12%
前日終値:
$16.87
開ける：
$17.07
24時間の取引高:
254.31K
Relative Volume:
0.62
時価総額：
$5.96B
収益：
$4.89B
当期純損益:
$-263.00M
株価収益率:
-21.77
EPS:
-0.7734
ネットキャッシュフロー:
$-167.84M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
-1.98%
6か月 パフォーマンス:
+17.60%
1年 パフォーマンス:
-3.50%
1日の値動き範囲:
$16.81
$17.14
1週間の範囲:
$16.74
$17.54
52週間の値動き範囲:
$10.45
$18.14
Bausch Lomb Corp Stock (BLCO) Company Profile
BLCO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.84 | 5.98B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
525.04 | 187.46B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
203.40 | 57.96B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.87 | 39.68B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.31 | 37.32B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
255.50 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2025-12-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Neutral |
| 2025-05-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-03-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 開始されました | Raymond James | Outperform |
| 2024-05-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 開始されました | Stifel | Hold |
| 2023-10-03 | 再開されました | Evercore ISI | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 開始されました | Needham | Hold |
| 2022-12-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-12 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-06-24 | 開始されました | Evercore ISI | Outperform |
| 2022-06-06 | 開始されました | Citigroup | Buy |
| 2022-05-31 | 開始されました | Deutsche Bank | Hold |
| 2022-05-31 | 開始されました | Goldman | Neutral |
| 2022-05-31 | 開始されました | Guggenheim | Buy |
| 2022-05-31 | 開始されました | JP Morgan | Neutral |
| 2022-05-31 | 開始されました | Jefferies | Buy |
| 2022-05-31 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 開始されました | Wells Fargo | Overweight |
| 2022-05-11 | 開始されました | Cowen | Outperform |
すべてを表示
Bausch Lomb Corp (BLCO) 最新ニュース
Bausch + Lomb Likely to Report a Q4 Beat on FX Tailwinds, Robust Performance of Eye Disease Portfolio, RBC Says - marketscreener.com
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $21 - 富途牛牛
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital - Investing.com
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital By Investing.com - Investing.com South Africa
Bausch Health stock unchanged as Phase 3 RED-C trial fails primary endpoint - Investing.com India
Bausch + Lomb Corp: Eyes On The Numbers As BLCO Tests Investor Patience - AD HOC NEWS
Growth Value: Is MLPR attractive for institutional investorsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - BioSpace
Press Release: Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - 富途资讯
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations - GlobeNewswire Inc.
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns By Investing.com - Investing.com Nigeria
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns - Investing.com Nigeria
Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Aug Patterns: Will Bausch Lomb Corporation outperform its industry peersJuly 2025 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Bausch + Lomb Corporation (BLCO) Stock Analysis: Navigating Growth in the Healthcare Sector - DirectorsTalk Interviews
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $19 - 富途牛牛
Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - GlobeNewswire Inc.
Published on: 2026-01-09 11:41:10 - Улправда
Will Bausch + Lomb Corporation (S2L) stock benefit from Fed rate cutsProduct Launch & Safe Entry Momentum Tips - ulpravda.ru
Bausch + Lomb (NYSE:BLCO) Rating Lowered to "Hold" at Evercore ISI - MarketBeat
Bausch + Lomb (NYSE:BLCO) Valuation Check After Mixed 90 Day And 1 Year Shareholder Returns - Yahoo Finance
Evercore Downgrades Bausch + Lomb Corp.(BLCO.US) to Hold Rating, Cuts Target Price to $18 - 富途牛牛
Bausch + Lomb Corporation (BLCO): Investor Outlook on Growth Potential and Strategic Positioning - DirectorsTalk Interviews
Glaucoma stories and research drive new Bausch + Lomb awareness push - Stock Titan
Bausch & Lomb CorpEnters fourth amendment to credit agreement dated as of May 10, 2022SEC filing - marketscreener.com
Bausch + Lomb just refinanced $2.8B in debt to cut interest margin - Stock Titan
Bausch + Lomb Signs Fourth Amendment to Credit Agreement With JPMorgan Chase and Lenders - TradingView — Track All Markets
Bausch + Lomb refinances term loans, extends maturities - TipRanks
Bausch + Lomb (BLCO): Investor Outlook on a Visionary Healthcare Player with a Focused Growth Trajectory - DirectorsTalk Interviews
Does Bausch + Lomb’s Rising Focus on Eye Health Make Its Current Share Price Attractive? - simplywall.st
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Top eye-care leaders to speak at J.P. Morgan's big healthcare event - Stock Titan
[8-K/A] Bausch & Lomb Corp Amends Material Event Report | BLCO SEC FilingForm 8-K/A - Stock Titan
Bausch + Lomb Makes Key Appointments to Board of Directors - VisionMonday.com
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Bausch + Lomb Corporation stock keep outperforming rivalsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Published on: 2025-12-18 17:17:15 - Улправда
Icahn Money Manager Sues His Bosses and Bausch + Lomb Over Anti-White Bias - Insurance Journal
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Globe and Mail
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans - VisionMonday.com
Bausch + Lomb appoints two new directors to board effective January - Investing.com
Bausch + Lomb Adds New Directors to Board - TipRanks
Bausch & Lomb Corp Announces Board Appointments - TradingView — Track All Markets
Bausch + Lomb appoints two new directors to board effective January By Investing.com - Investing.com South Africa
Bausch + Lomb (NYSE: BLCO) appoints Eduardo Alfonso and Steven Collis to board - Stock Titan
Bausch + Lomb Brief: Appointing Eduardo C. Alfonso, and Steven H. Collis To Its Board, Effective Jan. 1, 2026; Board Will Then Be Comprised of 10 Directors - marketscreener.com
Bausch + Lomb Announces Two Board Of Directors Appointments - TradingView — Track All Markets
Leading eye specialist and Fortune 10 CEO join Bausch + Lomb board - Stock Titan
Bausch + Lomb Corporation's (NYSE:BLCO) Prospects Need A Boost To Lift Shares - 富途牛牛
Large-Scale Debt Refinancing And Pipeline Optimism Might Change The Case For Investing In Bausch + Lomb (BLCO) - simplywall.st
(BLCO) Strategic Equity Report (BLCO:CA) - news.stocktradersdaily.com
Bausch Lomb Corp (BLCO) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.01%
大文字化:
|
ボリューム (24 時間):